Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Obstetrics and Gynecology

• Publication date

  2017-12-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajog.2017.12.221PMID 29288066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

  2020cited by this paper
• Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral

  2019cited by this paper
• Correction: Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral

  2017cited by this paper
• Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry

  2017cited by this paper
• Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

  2016cited by this paper
• Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.

  2016cited by this paper
• Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.

  2016cited by this paper
• Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis

  2015cited by this paper
• Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

  2015cited by this paper
• Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.

  2015cited by this paper
• Unit Costs of Health and Social Care 2016

  2015cited by this paper
• Hospitalization Costs for Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention in the United States Are Substantially Higher Than Medicare Payments

  2015cited by this paper
• RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.

  2015cited by this paper
• Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2

  2014cited by this paper
• Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

  2014cited by this paper
• Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

  2014influential reference
• Rates of risk‐reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers

  2014influential reference
• Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing

  2014cited by this paper
• Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.

  2014cited by this paper
• Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study

  2013cited by this paper
• Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses' Health Study.

  2013cited by this paper
• Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined

  2012cited by this paper
• Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.

  2012cited by this paper
• Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006–2009

  2012cited by this paper
• Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

  2011cited by this paper
• Reproductive and Hormonal Factors and Lung Cancer Risk in the NIH-AARP Diet and Health Study Cohort

  2011cited by this paper
• Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

  2011cited by this paper
• The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.

  2011cited by this paper
• Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

  2011cited by this paper
• Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

  2011cited by this paper
• Health outcomes in economic evaluation: the QALY and utilities.

  2010cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition

  2010cited by this paper
• Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

  2010cited by this paper
• Compliance with estrogen hormone replacement therapy after oophorectomy: a prospective study

  2010cited by this paper
• National Institute for Health and Clinical Excellence (NICE)

  2010cited by this paper
• National Institute for Health and Clinical Excellence

  2010cited by this paper
• Costs of Hormonal and Nonhormonal Prescription Medications for Hot Flashes

  2009cited by this paper
• Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent

  2009cited by this paper
• Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment.

  2009cited by this paper
• Prognosis of BRCA-associated breast cancer: a summary of evidence

  2009cited by this paper
• Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

  2009cited by this paper
• Increased cardiovascular mortality after early bilateral oophorectomy

  2009cited by this paper
• Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

  2009influential reference
• Breast cancer-related preferences among women with and without BRCA mutations

  2009cited by this paper
• Next-generation DNA sequencing

  2008cited by this paper
• Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

  2008influential reference
• Prophylactic oophorectomy in premenopausal women and long-term health

  2008cited by this paper
• Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

  2007cited by this paper
• Meta-analysis of BRCA1 and BRCA2 penetrance.

  2007cited by this paper
• Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

  2006cited by this paper
• Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2005influential reference
• Survival of metastatic breast carcinoma patients over a 20‐year period

  2005cited by this paper
• Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.

  2005cited by this paper
• BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder

  2005cited by this paper
• Unit Costs of Health and Social Care 2004

  2004cited by this paper
• Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area.

  2004cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004influential reference
• What is the price of life and why doesn't it increase at the rate of inflation?

  2003cited by this paper
• A Bayesian approach to Markov modelling in cost‐effectiveness analyses: application to taxane use in advanced breast cancer

  2003cited by this paper
• Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

  2002cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.

  1998cited by this paper
• Could the 185 deIAG BRCA1 Mutation Be an Ancient Jewish Mutation?

  1997cited by this paper
• Cigarette Smoking and Risk of Natural Menopause

  1990cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper

• Motherhood with HBOC in Israel: experiencing preventive disruption

  2025cites this paper
• The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review

  2025cites this paper
• Large-Scale Population Screening for BRCA1 and BRCA2 Ashkenazi Founder Mutations: Perspectives of Professionals Providing Oncogenetic Consultations

  2025cites this paper
• Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada

  2024cites this paper
• A cost-benefit analysis of genetic screening test for breast cancer in Iran

  2024cites this paper
• Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testing

  2023cites this paper
• Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians

  2023cites this paper
• Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review

  2022cites this paper
• Clinical case study meets population cohort: Identification of a BRCA1 pathogenic founder variant in Orcadians

  2022cites this paper
• Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies

  2022cites this paper
• A review of the cost-effectiveness of genetic testing for germline variants in familial cancer

  2022cites this paper
• Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy

  2022cites this paper
• Perspectives on Ovarian Cancer 1809 to 2022 and Beyond

  2022cites this paper
• Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population

  2021cites this paper
• Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies

  2021cites this paper
• Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations

  2021cites this paper
• A Systematic Review of the Methodological Quality of Economic Evaluations in Genetic Screening and Testing for Monogenic Disorders

  2021influential citation
• Preventive population genomics: The model of BRCA related cancers.

  2021cites this paper
• BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients

  2020cites this paper
• Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel

  2020cites this paper
• Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population

  2020cites this paper
• Population-based genetic testing for Women's cancer prevention.

  2020cites this paper
• Identification and characterisation of germline variants in an Irish cohort with breast cancer

  2020cites this paper
• A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies

  2020cites this paper
• Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.

  2020cites this paper
• A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm

  2019cites this paper
• Towards establishing consistency in triage in a tertiary specialty

  2019cites this paper
• Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

  2019cites this paper
• Breast cancer surveillance for BRCA1/2 mutation carriers – is “early detection” early enough?

  2019cites this paper
• Updates in Genetic Testing Guidelines for Breast Cancer Susceptibility Genes: a Change in the Paradigm

  2019cites this paper
• Randomised trial of population‐based BRCA testing in Ashkenazi Jews: long‐term outcomes

  2019cites this paper
• Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities

  2019cites this paper
• Population Based Testing for Primary Prevention: A Systematic Review

  2018influential citation
• Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

  2018cites this paper
• Population based germline testing for primary cancer prevention

  2018cites this paper